1.5 ML insulin icodec-abae 700 UNT/ML Pen Injector [Awiqli]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
1.5 ML insulin icodec-abae 700 UNT/ML Pen Injector [Awiqli]
700 UNT/ML · Pen Injector · injection
A form of insulin icodec-abae →
1.5 ML insulin icodec-abae 700 UNT/ML Pen Injector [Awiqli] — Insulins and analogues for injection, long-acting. Strength, form, class, interactions & more.
![1.5 ML insulin icodec-abae 700 UNT/ML Pen Injector [Awiqli]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5162b93e-5775-4581-a5e9-e8783ae0acd7&name=carton_3mL.jpg)
Active ingredient
Classification
Insulins and analogues for injection, long-acting
Drug interactions
The label outlines several drug interactions with insulin icodec-abae that can affect blood glucose levels.
- majorantidiabetic agents — may increase the risk of hypoglycemia
- majorACE inhibitors — may increase the risk of hypoglycemia
- majorangiotensin II receptor blocking agents — may increase the risk of hypoglycemia
- majordisopyramide — may increase the risk of hypoglycemia
- majorfibrates — may increase the risk of hypoglycemia
- majorfluoxetine — may increase the risk of hypoglycemia
- majormonoamine oxidase inhibitors — may increase the risk of hypoglycemia
- majorpentoxifylline — may increase the risk of hypoglycemia
- majorpramlintide — may increase the risk of hypoglycemia
- majorsalicylates — may increase the risk of hypoglycemia
- majorsomatostatin analogs (e.g., octreotide) — may increase the risk of hypoglycemia
- majorsulfonamide antibiotics — may increase the risk of hypoglycemia
- majorGLP-1 receptor agonists — may increase the risk of hypoglycemia
- majorDPP-4 inhibitors — may increase the risk of hypoglycemia
- majorSGLT-2 inhibitors — may increase the risk of hypoglycemia
- majoratypical antipsychotics (e.g., olanzapine and clozapine) — may decrease the blood glucose lowering effect
- majorcorticosteroids — may decrease the blood glucose lowering effect
- majordanazol — may decrease the blood glucose lowering effect
- majordiuretics — may decrease the blood glucose lowering effect
- majorestrogens — may decrease the blood glucose lowering effect
- majorglucagon — may decrease the blood glucose lowering effect
- majorisoniazid — may decrease the blood glucose lowering effect
- majorniacin — may decrease the blood glucose lowering effect
- majororal contraceptives — may decrease the blood glucose lowering effect
- majorphenothiazines — may decrease the blood glucose lowering effect
- majorprogestogens (e.g., in oral contraceptives) — may decrease the blood glucose lowering effect
- majorprotease inhibitors — may decrease the blood glucose lowering effect
- majorsomatropin — may decrease the blood glucose lowering effect
- majorsympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) — may decrease the blood glucose lowering effect
- majorthyroid hormones — may decrease the blood glucose lowering effect
- moderatealcohol — may increase or decrease the blood glucose lowering effect
- moderatebeta-blockers — may increase or decrease the blood glucose lowering effect and may blunt signs and symptoms of hypoglycemia
- moderateclonidine — may increase or decrease the blood glucose lowering effect and may blunt signs and symptoms of hypoglycemia
- moderatelithium salts — may increase or decrease the blood glucose lowering effect
- unknownpentamidine — may cause hypoglycemia, which may sometimes be followed by hyperglycemia
- unknownguanethidine — may blunt signs and symptoms of hypoglycemia
- unknownreserpine — may blunt signs and symptoms of hypoglycemia
Real-world adverse events (FAERS)
Glycosylated Haemoglobin Increased2Angiosarcoma1Atrial Fibrillation1Blood Albumin Increased1Cataract1Coronary Artery Disease1Diabetic Neuropathy1Diabetic Retinopathy1
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication